Cantor Fitzgerald Weighs in on Corvus Pharmaceuticals, Inc.’s FY2022 Earnings (NASDAQ:CRVS)

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVSGet Rating) – Stock analysts at Cantor Fitzgerald issued their FY2022 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a research report issued to clients and investors on Wednesday, September 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings per share of ($0.69) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.96) per share. Cantor Fitzgerald also issued estimates for Corvus Pharmaceuticals’ FY2023 earnings at ($0.76) EPS.

Corvus Pharmaceuticals (NASDAQ:CRVSGet Rating) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01.

Separately, StockNews.com started coverage on Corvus Pharmaceuticals in a report on Friday, July 1st. They set a “sell” rating for the company.

Corvus Pharmaceuticals Price Performance

Shares of Corvus Pharmaceuticals stock opened at $0.78 on Friday. The firm has a market cap of $36.31 million, a price-to-earnings ratio of -0.97 and a beta of 0.90. Corvus Pharmaceuticals has a 52-week low of $0.75 and a 52-week high of $8.11. The stock has a 50-day simple moving average of $0.96 and a 200-day simple moving average of $1.17.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Several institutional investors have recently made changes to their positions in CRVS. Point72 Asset Management L.P. lifted its holdings in shares of Corvus Pharmaceuticals by 38.3% during the 4th quarter. Point72 Asset Management L.P. now owns 795,000 shares of the company’s stock valued at $1,916,000 after buying an additional 220,000 shares during the last quarter. Jackson Square Capital LLC bought a new position in shares of Corvus Pharmaceuticals in the 1st quarter valued at approximately $105,000. Renaissance Technologies LLC raised its stake in shares of Corvus Pharmaceuticals by 6.9% in the 2nd quarter. Renaissance Technologies LLC now owns 962,932 shares of the company’s stock valued at $953,000 after acquiring an additional 61,800 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Corvus Pharmaceuticals by 72.6% in the 1st quarter. Acadian Asset Management LLC now owns 140,118 shares of the company’s stock valued at $228,000 after acquiring an additional 58,952 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Corvus Pharmaceuticals by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 1,267,752 shares of the company’s stock valued at $2,079,000 after acquiring an additional 36,002 shares in the last quarter. 55.02% of the stock is currently owned by institutional investors and hedge funds.

About Corvus Pharmaceuticals

(Get Rating)

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers.

Featured Articles

Earnings History and Estimates for Corvus Pharmaceuticals (NASDAQ:CRVS)

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.